Autoimmune rhabdomyolysis and a multiorgan display of PD-1 inhibitor induced immune related adverse events during treatment of metastatic melanoma

BACKGROUND: Programmed death-1 (PD-1) inhibitors are among the immunotherapies that have revolutionized our approach to treating several cancers. These novel agents act by blocking PD-1 receptor/PD-1 ligand interactions that would otherwise allow tumor cells to evade host immune destruction by inhib...

Descripción completa

Detalles Bibliográficos
Autores principales: Pourhassan, Hoda Z., Tryon, David, Schaeffer, Brett, Mirshahidi, Hamid, Wong, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734285/
https://www.ncbi.nlm.nih.gov/pubmed/31516766
http://dx.doi.org/10.1186/s40164-019-0140-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734285/
https://www.ncbi.nlm.nih.gov/pubmed/31516766
http://dx.doi.org/10.1186/s40164-019-0140-2

Ejemplares similares